This Could Spell Bad News for Novavax
Novavax (NASDAQ: NVAX) investors are likely feeling frustrated. First, they had to wait as the company delayed filing for an Emergency Use Authorization (EUA) for its COVID-19 vaccine. And now, after the company filed for an EUA in late January, they are waiting on the Food and Drug Administration (FDA) to authorize it.
Although there hasn't been a formal announcement from the agency that Novavax won't obtain the authorization, the writing could be on the wall that another vaccine may not be necessary for the U.S. market. And a recent development involving another vaccine maker could confirm the worst for Novavax investors.
Image source: Getty Images.
Source Fool.com
